Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.
about
Multimodal management of muscle-invasive bladder cancerSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Update on advances in molecular PET in urological oncologyOptimal Modality for Detecting Distant Metastasis in Primary Nasopharyngeal Carcinoma during Initial Staging: A Systemic Review and Meta-analysis of 1774 PatientsManagement of urological malignancies: Has positron emission tomography/computed tomography made a difference?Efficacy of (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy.PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.Extraperitoneal urinary bladder perforation detected by FDG PET/CT.Detecting Metastatic Bladder Cancer Using (18)F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography.PET/CT and MRI in Bladder Cancer.Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in penile cancer.Contrast enhanced computed tomography characterization of fluorodeoxygluocose-avid regional and non-regional lymph nodes in patients with suspicion of metastatic bladder cancer.Role of consolidative surgical therapy in patients with locally advanced or regionally metastatic bladder cancer.Update on use of enhanced imaging to optimize lymphadenectomy in patients undergoing minimally invasive surgery for urothelial cancer of the bladder.Current role of PET, CT, MR for invasive bladder cancer.Evolving role of positron emission tomography (PET) in urological malignancy.Preoperative imaging for staging bladder cancer.Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis.Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.EpCAM Expression in Lymph Node Metastases of Urothelial Cell Carcinoma of the Bladder: A Pilot Study.Current Staging Procedures in Urinary Bladder CancerCurrent Concepts in the Management of Muscle Invasive Bladder Cancer.Advances in medical imaging for the diagnosis and management of common genitourinary cancers.Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer.Comparing RECIST with EORTC criteria in metastatic bladder cancer.Forced diuresis (18)F-fluorodeoxyglucose positron emission tomography/contrast enhanced in detection of carcinoma of urinary bladder diverticulum.Detecting primary bladder cancer using delayed (18)F-2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography imaging after forced diuresis.Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.[Functional imaging in bladder cancer].A new method for detecting urinary bladder cancer by using FDG PET/CT.Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.Is 18F-FDG PET/CT more reliable than 99mTc-MDP planar bone scintigraphy in detecting bone metastasis in nasopharyngeal carcinoma?Fluorodeoxyglucose positron-emission tomography (FDG PET)/computed tomography (CT) in bladder cancer.Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study.Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy.
P2860
Q27011624-E291E9D5-C1B0-4F08-8660-9EDCBFF02C7DQ30240816-E1202B47-4262-48E3-BCED-3B1E949A2E49Q33625389-CC7DDF2D-D756-49A7-A03A-C66E297AB6BCQ33776738-DDC6E6F8-A216-409F-A727-9DDE1025AC23Q34990800-95AD87A5-7947-4DB3-9847-350E6EB4DDCAQ35048726-D85524DA-E401-40C4-946D-FC2F497FE485Q35776939-5FC3D180-CD62-4F71-A550-AEDB722AB6AFQ35829306-9D5CA5F0-89BC-42E3-9349-817B9A57A8B9Q36187084-C11E5121-11AE-460E-A4B9-AD84A771F38CQ36654987-8EE0BFA5-2E2F-4F9A-BE7F-FBE70C4E3EF0Q37565552-1DDDB1F5-0B4F-4166-9D9E-0874AB64E2BBQ37604110-2D680590-5106-45CD-831C-19A757FD5A28Q37679778-4C6F9AF2-979B-46CA-A941-7FE37B1A5F2BQ38076094-F998BEE2-1031-4279-BEEF-35E575F4D46DQ38080034-20815297-CFDE-43BB-B03B-27E3A1AD1E22Q38269763-DFD34B64-2490-4A49-BD5A-09FA28D2FEA6Q38365924-8E7FF4D3-21FA-4F89-AF1E-14BEF3B8CB8AQ38391343-DC84EAD2-9CAD-4462-8795-16547DDC88A7Q38540198-A4BB6310-257F-4D5C-B617-2218735F6814Q38618544-4BF3A860-DE46-47B6-B456-A62A3AA975B3Q38715998-09E55E45-A8FC-4055-88F2-D38E4573FA63Q39105784-36797743-BD34-4EBC-9B9D-32EC191C62ACQ39307896-B63CF192-8C86-41A5-AE86-E805F94F9910Q39450381-6EF6CD34-4FD9-4F3F-816E-F230AEB66CB8Q39614979-26E8A95E-3461-4686-840E-ED96E6ABBA21Q40076302-C904D0E6-3C75-46ED-88D0-AB7F6AC09D99Q40699016-F41D2D76-54FF-4993-A7E0-919202437F90Q42284604-DACB424B-3B0D-44CD-8AF9-44AF5003979FQ43066911-48A86E92-6F62-4CAB-9785-047E5E9007F8Q44978946-9F7B6917-4729-4B3A-B527-63B3CDCA1823Q45909222-86CB9AA1-56FB-4849-BFC9-188DBD4C4794Q45917976-38990C89-348F-42EF-A4A2-7367EC819E43Q47207206-EEE11F9C-F5C2-46E5-9320-8B0270685AC5Q49165684-1F527C37-51D3-4FC6-9952-76981CD27ABEQ53076138-79AED38E-F03E-4F0D-9C43-E36BF4EA4FBEQ53090496-CF25A18C-528A-4B1B-B568-B92A109AE14CQ53104789-99F545D3-882B-47D8-891C-E0C93CFDF190Q53126609-E5F2AF41-312B-48EF-ADD6-4BF33F310C05Q53153694-F0426A74-B5F9-42C5-9826-85D24F7DF2F1Q53631599-12B28145-69F7-4702-B3AC-C32974AA23C5
P2860
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical value of fluorine-18 ...... tomography in bladder cancer.
@ast
Clinical value of fluorine-18 ...... tomography in bladder cancer.
@en
Clinical value of fluorine-18 ...... tomography in bladder cancer.
@nl
type
label
Clinical value of fluorine-18 ...... tomography in bladder cancer.
@ast
Clinical value of fluorine-18 ...... tomography in bladder cancer.
@en
Clinical value of fluorine-18 ...... tomography in bladder cancer.
@nl
prefLabel
Clinical value of fluorine-18 ...... tomography in bladder cancer.
@ast
Clinical value of fluorine-18 ...... tomography in bladder cancer.
@en
Clinical value of fluorine-18 ...... tomography in bladder cancer.
@nl
P2093
P2860
P356
P1476
Clinical value of fluorine-18 ...... tomography in bladder cancer.
@en
P2093
Alisa Trout
Andrea B Apolo
Dean F Bajorin
Heiko Schöder
Jamie Riches
Matthew I Milowsky
P2860
P304
P356
10.1200/JCO.2010.28.7052
P407
P50
P577
2010-08-02T00:00:00Z